Pharmacy benefit managers are finding themselves in the spotlight more than they used to — and their top lobbyist doesn’t mind.

PBMs and the lobbyists who advocate for them, unsurprisingly, see things differently from Congressman Doug Collins of Georgia, a Republican who last week excoriated PBMs in an interview with STAT. STAT also spoke with Mark Merritt, the CEO of the Pharmaceutical Care Management Organization, about how PBMs view their work.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • What a bunch of crap this guy is throwing at you ! There is only one type of transparency ! and the PBM’s don’t want anybody to see what they’re doing.
    Ask the PBM’s to show their clients how much they reimburse pharmacies.
    Who keeps the hundred’s of millions of dollars they’re stealing in D.I.R fees?
    Why do they still base their drug cost on a ficticous number (AWP) ?
    It’s all smoke and mirrors so they can continue to rob from all of us.
    Why are PBM’s still reimbursing pharmacies $50-$75 below their cost on prescriptions?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy